SCHEMBL5655092

SCHEMBL5655092

COc1ccc(-c2[c]c3c(N)ncnc3o2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 9/20 0.53
KDR P35968 8/20 0.53
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
UBE2N P61088 1/20 0.49
MAP4K4 O95819 1/20 0.45
GSK3B P49841 1/20 0.45
DGAT1 O75907 1/20 0.42
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
HSD17B10 Q99714 1/20 0.40
DYRK1A Q13627 1/20 0.40
CLK1 P49759 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gw642138X SCHEMBL5404724 0.73 EGFR (0.57) TEKKDRMAP4K4GSK3BEGFR
SCHEMBL14013977 0.69 TEK (0.74) TEKKDRKDM4EALDH1A1HPGD
SCHEMBL14013972 0.69 TEK (0.74) TEKKDRKDM4EALDH1A1HPGD
Gw642125X SCHEMBL14013971 0.68 KDR (1.00) TEKKDRKDM4EALDH1A1HPGD
SCHEMBL14013982 0.67 TEK (0.92) TEKKDRKDM4EALDH1A1HPGD
SCHEMBL12355051 0.66 KDM4E (1.00) TEKKDRKDM4EALDH1A1HPGD
SCHEMBL14923113 0.66 KDM4E (1.00) TEKKDRKDM4EALDH1A1HPGD
SCHEMBL30782553 0.64 TEK (0.54) TEKKDRKDM4EALDH1A1HPGD
SCHEMBL28001140 0.63 DYRK1A (0.60) KDM4EALDH1A1SMN1; SMN2MAP4K4NPC1
SCHEMBL6409547 0.62 EGFR (0.57) KDRHPGDGSK3BEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185098-A1 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185098-A1 Inhibitors of protein kinases MAP3K20, MAP3K1, MAP3K19 TEK 1180/4885KDR 960/4885KDM4E 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.